Headquartered in Miami, FL Fiscal year ends December NASDAQ: OPK opko.com
OPKO Health is a multinational biopharmaceutical and diagnostics company operating across two primary segments. Its diagnostics division, anchored by subsidiary BioReference Health, provides clinical laboratory testing services including core diagnostics and the 4Kscore prostate cancer test. The pharmaceutical segment encompasses international operations (primarily in Spain and Mexico), the Rayaldee product for secondary hyperparathyroidism, and a growing pipeline of biologics through its ModeX subsidiary, which develops multispecific antibodies and T-cell engagers targeting oncology and autoimmune diseases. OPKO also generates revenue through partnerships including an NGENLA profit-sharing arrangement with Pfizer, a BARDA-funded COVID-19 prevention program, and collaborations with Regeneron and Eli Lilly. The company has strategic partnerships with Entera Bio for oral peptide therapeutics and Nicoya for Rayaldee commercialization in Greater China. OPKO Biologics is advancing long-acting biologic therapies including a growth hormone receptor antagonist for acromegaly and a dual GLP-1/Glucagon agonist for MASH. Updated
With a market rotation underway, where should investors seeking opportunities in health care be looking? Analysts have high expectations for Alphatec.
Insider buying was somewhat slow in the middle of January, but some purchases by Warren Buffett's Berkshire Hathaway made headlines.
As the year got underway, biotechs were in focus among the notable insider buying, especially in two companies focused on treatments for the eye.
OPKO Health is a multinational biopharmaceutical and diagnostics company operating across two primary segments. Its diagnostics division, anchored by subsidiary BioReference Health, provides clinical laboratory testing services including core diagnostics and the 4Kscore prostate cancer test.
The Wall Street consensus 12-month price target for OPK is $4.38.
